Characteristics of patients who underwent unrelated donor transplantation for AML in second complete remission, by cytogenetics risk group
| Variable . | Favorable . | Intermediate . | Unfavorable . |
|---|---|---|---|
| No. of patients | 97 | 165 | 37 |
| Age at transplantation, median (range), y | 25 (2-50) | 25 (1-58) | 21 (2-58) |
| Age at transplantation, no. (%) | |||
| Younger than 20 y | 41 (42) | 65 (39) | 18 (49) |
| 20 to 40 y | 40 (42) | 56 (34) | 10 (27) |
| Older than 40 y | 16 (16) | 44 (27) | 9 (24) |
| Karnofsky score at transplantation, no. (%) | |||
| Less than 90 | 18 (19) | 44 (27) | 12 (32) |
| 90 or more | 77 (79) | 118 (71) | 24 (65) |
| Unknown | 2 (2) | 3 (2) | 1 (3) |
| CMV status, no. (%) | |||
| Positive | 37 (38) | 84 (51) | 20 (54) |
| Negative | 58 (60) | 79 (48) | 16 (43) |
| Unknown | 2 (2) | 2 (1) | 1 (3) |
| Conditioning regimen, no. (%) | |||
| BuCy ± other | 12 (12) | 24 (15) | 7 (19) |
| CyTBI ± other | 79 (82) | 129 (78) | 30 (81) |
| Other | 6 (6) | 12 (7) | 0 |
| Duration of first CR, median (range), mo | 11 (1-38) | 10 (<1-43) | 8 (< 1-28) |
| Nucleated cell dose, median (range), × 108/kg | 2 (<1-11) | 3 (<1-17) | 3 (< 1-21) |
| Donor-recipient sex match, no. (%) | |||
| Female-female | 17 (18) | 29 (17) | 8 (22) |
| Female-male | 17 (18) | 28 (17) | 8 (22) |
| Male-female | 24 (24) | 44 (27) | 10 (27) |
| Male-male | 39 (40) | 64 (39) | 11 (29) |
| Donor-recipient CMV match, no. (%) | |||
| +/+ | 20 (21) | 33 (20) | 10 (27) |
| +/− | 18 (19) | 27 (16) | 4 (11) |
| −/+ | 17 (17) | 51 (31) | 10 (27) |
| −/− | 39 (40) | 52 (32) | 12 (32) |
| Unknown | 3 (3) | 2 (1) | 1 (3) |
| Donor-recipient HLA match, no. (%) | |||
| Match | 74 (76) | 122 (74) | 27 (73) |
| Mismatch | 23 (24) | 43 (26) | 10 (27) |
| Year of transplantation, no. (%) | |||
| 1988 to 1993 | 6 (6) | 14 (8) | 3 (8) |
| 1994 to 1997 | 36 (37) | 58 (35) | 8 (21) |
| 1998 to 2002 | 55 (57) | 93 (57) | 26 (71) |
| GVHD prophylaxis, no. (%) | |||
| CsA + MTX ± other | 41 (42) | 89 (54) | 16 (43) |
| FK506 ± other | 17 (18) | 35 (21) | 5 (13) |
| T-cell depletion | 36 (37) | 37 (22) | 15 (41) |
| Other | 3 (3) | 4 (3) | 1 (3) |
| Median follow-up of survivors, mo (range) | 60 (6-155) | 60 (6-112) | 52 (30-133) |
| Variable . | Favorable . | Intermediate . | Unfavorable . |
|---|---|---|---|
| No. of patients | 97 | 165 | 37 |
| Age at transplantation, median (range), y | 25 (2-50) | 25 (1-58) | 21 (2-58) |
| Age at transplantation, no. (%) | |||
| Younger than 20 y | 41 (42) | 65 (39) | 18 (49) |
| 20 to 40 y | 40 (42) | 56 (34) | 10 (27) |
| Older than 40 y | 16 (16) | 44 (27) | 9 (24) |
| Karnofsky score at transplantation, no. (%) | |||
| Less than 90 | 18 (19) | 44 (27) | 12 (32) |
| 90 or more | 77 (79) | 118 (71) | 24 (65) |
| Unknown | 2 (2) | 3 (2) | 1 (3) |
| CMV status, no. (%) | |||
| Positive | 37 (38) | 84 (51) | 20 (54) |
| Negative | 58 (60) | 79 (48) | 16 (43) |
| Unknown | 2 (2) | 2 (1) | 1 (3) |
| Conditioning regimen, no. (%) | |||
| BuCy ± other | 12 (12) | 24 (15) | 7 (19) |
| CyTBI ± other | 79 (82) | 129 (78) | 30 (81) |
| Other | 6 (6) | 12 (7) | 0 |
| Duration of first CR, median (range), mo | 11 (1-38) | 10 (<1-43) | 8 (< 1-28) |
| Nucleated cell dose, median (range), × 108/kg | 2 (<1-11) | 3 (<1-17) | 3 (< 1-21) |
| Donor-recipient sex match, no. (%) | |||
| Female-female | 17 (18) | 29 (17) | 8 (22) |
| Female-male | 17 (18) | 28 (17) | 8 (22) |
| Male-female | 24 (24) | 44 (27) | 10 (27) |
| Male-male | 39 (40) | 64 (39) | 11 (29) |
| Donor-recipient CMV match, no. (%) | |||
| +/+ | 20 (21) | 33 (20) | 10 (27) |
| +/− | 18 (19) | 27 (16) | 4 (11) |
| −/+ | 17 (17) | 51 (31) | 10 (27) |
| −/− | 39 (40) | 52 (32) | 12 (32) |
| Unknown | 3 (3) | 2 (1) | 1 (3) |
| Donor-recipient HLA match, no. (%) | |||
| Match | 74 (76) | 122 (74) | 27 (73) |
| Mismatch | 23 (24) | 43 (26) | 10 (27) |
| Year of transplantation, no. (%) | |||
| 1988 to 1993 | 6 (6) | 14 (8) | 3 (8) |
| 1994 to 1997 | 36 (37) | 58 (35) | 8 (21) |
| 1998 to 2002 | 55 (57) | 93 (57) | 26 (71) |
| GVHD prophylaxis, no. (%) | |||
| CsA + MTX ± other | 41 (42) | 89 (54) | 16 (43) |
| FK506 ± other | 17 (18) | 35 (21) | 5 (13) |
| T-cell depletion | 36 (37) | 37 (22) | 15 (41) |
| Other | 3 (3) | 4 (3) | 1 (3) |
| Median follow-up of survivors, mo (range) | 60 (6-155) | 60 (6-112) | 52 (30-133) |
BU indicates bulsulfan; CY, cyclophosphamide; TBI, total body irradiation; CMV, cytomegalovirus; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate; CR, complete remission; and FK506, tacrolimus.